Evidence map›Paper›PMID 34503284›Full record

ArticleCancers2021

Targeting

Chin-Li Chen, En Meng, Sheng-Tang Wu, Hsing-Fan Lai, Yi-Shan Lu, Ming-Hsin Yang, Chih-Wei Tsao, Chien-Chang Kao, Yi-Lin Chiu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.Journal of experimental & clinical cancer research : CR · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chin-Li ChenDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
En MengDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Sheng-Tang WuDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Hsing-Fan LaiDepartment of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
Yi-Shan LuDepartment of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
Ming-Hsin YangDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Chih-Wei TsaoDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Chien-Chang KaoDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Yi-Lin ChiuDepartment of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
Tri-Service General Hospital · TWNational Defense Medical Center · TW

Funding

Ministry of National Defense-Medical Affairs Bureau MND-MAB-110-058Ministry of National Defense-Medical Affairs Bureau MND-MAB-110-122Ministry of Science and Technology, Taiwan MOST109-2320-B-016-004
6 · The paper itself

Abstract

Clinical bladder tumor histological analysis shows that high expression of

Indexed as

bladder carcinomacell migrationepithelial–mesenchymal transitionFTY-720sphingosine 1-phosphate receptor 1

Identifiers

PMID34503284
PMCPMC8431630
OpenAlexW3198804687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.